Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4HF-03
- Development stage
- Preclinical
- Lead developer
- 4HF Biotec
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
4HF-03 is an early-stage small molecule drug conjugate (SMDC) being developed by 4HF Biotec for the treatment of prostate cancer. The drug is designed using the company's proprietary AI and data mining platform, which identifies specific cancer targets to enable precision medicine. As an SMDC, 4HF-03 is engineered to deliver a therapeutic payload directly to cancer cells by utilizing a targeting ligand, thereby potentially increasing efficacy and reducing systemic side effects compared to traditional chemotherapy. It is currently in the discovery phase, specifically undergoing in silico chemistry and medicinal chemistry optimization.
Beyond the preview
Go deeper on 4HF-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4HF-03.